Hepatitis therapy: Kupffer cells adjust the balance between pathogen control and hepatocyte regenera

January 17, 2018, Elsevier

Inflammation of the liver can result from different causes. Besides infections with hepatitis B virus (HBV) and hepatitis C virus (HCV), other viruses such as cytomegalovirus (CMV) are able to trigger acute hepatitis. Sometimes hepatitis induces fever and flu-like symptoms, however, it may also damage the liver and might even result in acute liver failure. Yet, currently there is no general agreement on how acute hepatitis should be treated: Should the immune response against the viral pathogen be reinforced or inhibited? Scientists from TWINCORE have now published new insights on the processes involved in liver inflammation in the Journal of Hepatology: Type I interferons, on the one hand, limit viral replication and thereby help the immune cells to control the viral pathogen. On the other hand, type I interferons delay the regeneration of immune cells, which are important to adjust and maintain the immune balance within the liver during acute inflammation.

"So far, it has been assumed that viral replication itself destroys ," says Katharina Borst, scientist at the Institute for Experimental Infection Research, TWINCORE, Hannover, Germany. "Meanwhile we also know that local inflammatory processes can damage the liver." This is critical knowledge, because, if the inflammatory reaction and not the virus accounts for liver damage, one should not enhance the inflammation within the already inflamed organ by treatment with an inflammatory cytokine such as type I interferon. "On the other hand, in clinical practice it is well established that type I interferon is an effective treatment during acute hepatitis and that it protects the liver," argues Dr. Theresa Frenz, also scientist at the Institute for Experimental Infection Research, TWINCORE. At first glance this is a paradoxical situation that needs clarification.

Therefore, the scientists set out to understand the mechanism by which type I interferon works in the liver. To understand the local immune responses, they analyzed Kupffer , which are liver-resident scavenger cells within the immune system. The researchers used vaccinia virus to infect livers that either could or could not detect type I interferon, or in which only the Kupffer cells or the hepatocytes, the main cell type of the liver, could or could not detect type I interferon.

"This experiment showed us that hepatocytes do not need type I interferon to combat viral infection, since we could not find differences, regardless of whether we analyzed normal livers or livers in which only hepatocytes did not detect type I interferon," says Katharina Borst. "This is surprising, since hepatocytes are the main target cell for type for infection."

However, type I interferon seems to be important for Kupffer cells, says Dr. Frenz: "We believe, that type I interferon triggers Kupffer cells to take up infected cells and undergo apoptosis (suicide) afterwards, since surprisingly, Kupffer cells disappear after infection." The body replaces those lost Kupffer cells by scavenger cells, which develop from the bone marrow. Such cells are not "real" Kupffer cells, but they still take over similar tasks. Interestingly, this process is accelerated if the cannot sense type I interferon," says Ms. Borst. "Obviously, type I interferon is very important to adjust the regulation of inflammatory processes."

"We verified that therapeutic treatment of acute viral hepatitis with type I interferon is reasonable, since it activates local and helps to eliminate the virus," concludes institute director Prof. Ulrich Kalinke. "However, in order to better support the regeneration of the inflamed , we need to learn more about the balance of enhancement and modulation of inflammation. This will be the basis to develop new therapeutic interventions for ."

Explore further: Effect of gut bacteria on specific immune cells underlies persistent liver inflammation

More information: Katharina Borst et al, Type I interferon receptor-signaling delays Kupffer cell replenishment during acute fulminant viral hepatitis, Journal of Hepatology (2017). DOI: 10.1016/j.jhep.2017.11.029

Related Stories

Effect of gut bacteria on specific immune cells underlies persistent liver inflammation

January 16, 2018
Persistent liver inflammation in sufferers of chronic viral hepatitis is likely caused by interactions between pro-inflammatory immune cells in the liver and products from gut bacteria, according to new work involving A*STAR ...

Hepatitis C virus tricks liver cells to sabotage immune defenses

November 17, 2016
The virus that causes hepatitis C protects itself by blocking signals that call up immune defenses in liver cells, according to University of Washington researchers and colleagues reporting Nov. 14 in Nature Medicine.

Zinc may hold key to fighting liver disease

June 1, 2017
New research from the Westmead Institute's Storr Liver Centre in collaboration with the Centre for Virus Research and Kirby Institute has shown that serum zinc may benefit liver disease in a way we never expected.

New interferon shows promise against hepatitis B in cell culture, and animal model

April 3, 2017
Hepatitis B is notoriously difficult to eradicate with currently available agents.. Now, in a new study, a novel form of "pegylated" interferon-β has reduced hepatitis B virus (HBV) infections in experimental human-derived ...

Team identifies how hepatitis A virus causes liver injury

September 15, 2016
Hepatitis researchers have long thought that immune cells sent by the body to attack virus-infected cells in the liver cause the acute liver injury associated with hepatitis A virus (HAV) and other hepatitis viruses. Yet, ...

Signal flare – how heart muscle cells protect themselves from viral invaders

September 29, 2017
The human heart is particularly vulnerable to viruses. That's because cardiac myocytes, the heart muscle cells that give your heart its ability to "beat," have one major weakness – they don't reproduce themselves to repair ...

Recommended for you

'Game changer' tuberculosis drug cures 9 in 10

October 22, 2018
A new treatment for a drug-resistant strain of tuberculosis can cure more than 90 percent of sufferers, according to a trial hailed Monday as a "game changer" in the fight against the global killer.

AI doctor could boost chance of survival for sepsis patients

October 22, 2018
Scientists have created an artificial intelligence system that could help treat patients with sepsis.

Consuming caffeine from coffee reduces incident rosacea

October 22, 2018
(HealthDay)—Caffeine intake from coffee is inversely associated with the risk for incident rosacea, according to a study published online Oct. 17 in JAMA Dermatology.

Home-based biofeedback therapy is effective option for tough-to-treat constipation

October 22, 2018
Biofeedback therapy used at home is about 70 percent effective at helping patients learn how to coordinate and relax bowel muscles and relieve one of the most difficult-to-treat types of constipation, investigators report.

A guide to Acute flaccid myelitis (AFM), the rare, polio-like illness making young children sick

October 22, 2018
A fast-acting, polio-like illness has sickened 62 young children, with an average age of 4, in 22 U.S. states so far this fall.

Scientists in Sweden may have figured out one way acne bacteria defies treatment

October 22, 2018
Researchers in Sweden have discovered how acne-causing bacteria feed off their human hosts. The study, which was performed at KTH Royal Institute of Technology, could make it possible to find effective ways to treat severe ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.